Brii Biosciences Ltd HBV R&D Day Transcript
(foreign language) Ladies and gentlemen, good afternoon. Welcome everyone to Brii Biosciences virtual HBV R&D Day. I am today's host, Rico Liang, General Manager of Brii Biosciences, Greater China. On behalf of Brii Biosciences, I would like to express my gratitude to all of you and welcome any questions during the meeting. We will have a Q&A session by the end of the meeting.
Firstly, please allow me to introduce the guest of today. They are Professor Zhuang Hui of Chinese Academy of Engineering; Dr. Hong Zhi, Chairman and CEO of Brii Bio; Dr. Yongqing , China R&D Head of Brii Bio. Thank you so much for your participation. Chronic Hepatitis B is one of the most serious infectious disease in the world with more than 250 million affected people. In particular, China is facing with heavy burden of this disease. Latest administrative research results shows that HBV infection rate in China is 5.6%, covering 79 million people and about 400,000 new infection are related to liver cancer (inaudible) every day. For a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |